Navigation Links
Exagen Diagnostics Names John Alsobrook, Ph.D., Vice President and Chief Operating Officer
Date:2/17/2009

ALBUQUERQUE, N.M., Feb. 17 /PRNewswire/ -- Exagen Diagnostics, Inc., which provides proprietary molecular diagnostics testing services, genomic probes for research and analytic specific reagents to clinical laboratories and academic institutions, today announced that John Alsobrook, Ph.D., has been named vice president and chief operating officer. In his new role, Alsobrook oversees Exagen's day-to-day operations, company alliances and genomic marker discovery and development programs. He reports to Exagen Founder and Interim CEO Waneta Tuttle, Ph.D., M.B.A.

Alsobrook joined Exagen in 2006 as the company's director of genomic marker discovery, responsible for quality control and analysis of genomic data using both standard statistical approaches and Exagen's proprietary data mining engine. He played a key role in the development of the company's initial prognostic marker test that identifies the risk of recurrence in certain breast cancer patients. Alsobrook has also led the company's development of diagnostic tests for patients with gastroenterological conditions such as irritable bowel syndrome and inflammatory bowel disorder.

"John's extensive background in genomic science has provided Exagen with invaluable insight as the company develops new products and services for clinical laboratories and academic institutions," said Dinesh Patel, Ph.D., Exagen board chairman and managing director at investment firm vSpring Capital. "His experience and proven leadership skills make him a key member of the management team that will lead Exagen into the next phase of growth," Patel added.

Alsobrook has nearly 30 years of industry and faculty experience in scientific management, research and project consulting. Prior to joining Exagen, he worked as a consultant for clients including Genaissance Pharmaceuticals, Amersham Health, G.E. Healthcare and Massachusetts General Hospital. Alsobrook also worked at CuraGen Corp. as genetics supervisor for drug discovery and as senior research scientist for pharmacogenomics. From 1996-2000, Alsobrook was associate faculty scientist at Yale School of Medicine Child Study Center, where he investigated inherited psychiatric disorders. He holds B.S. degrees in biochemistry and physics from California State University Los Angeles, and both an M. Phil. and a Ph.D. from Yale University's Department of Genetics.

About Exagen Diagnostics, Inc.

Exagen Diagnostics is a CLIA-registered molecular diagnostics laboratory with a growing menu of proprietary, internally developed genomic tests. Exagen also sells genomic probes for research use and analyte specific reagents to other clinical laboratories and academic institutions. For more information, visit www.exagen.com.


'/>"/>
SOURCE Exagen Diagnostics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Quest Diagnostics to Speak at the Bear Stearns Healthcare Conference
2. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
3. Hypertension Diagnostics Announces Fiscal Year 2007 Results
4. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
5. Meretek Diagnostics and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger
6. Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software
7. Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative
8. HealthShares(TM) Announces Changes to the HealthShares(TM) Diagnostics and Composite Indexes
9. Optherion Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostics Based on Chromosome 10 Genetic Variations
10. Quest Diagnostics Reports Third Quarter Results
11. ICx Technologies and Siemens Medical Solutions Diagnostics Enter In Vitro Diagnostics Development and License Option Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many of ... beholder, according to experts who offered insights and commentary in the current issue of ... full issue, click here . , For the American Society of Clinical Oncology ...
(Date:6/26/2016)... ... ... a legally blind and certified personal trainer is helping to develop a weight loss fitness ... to fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
Breaking Medicine Technology: